Skip to main content
. 2016 Nov 2;311(6):R1223–R1233. doi: 10.1152/ajpregu.00362.2016

Fig. 5.

Fig. 5.

Effect of Lenti-mACE2 gene therapy on fasting blood glucose and glucose intolerance in HFD-fed mice. Twelve weeks after HFD-feeding, HFD + Lenti-GFP showed significantly higher fasting blood glucose (A) and glucose intolerance (B) compared with RD + Lenti-GFP mice. Three weeks after the pancreatic injection of Lenti-mACE2 (n = 8) or the control lentivirus Lenti-GFP (n = 10), fasting blood glucose levels (C) and glucose intolerance (D and E) were significantly reduced in HFD + Lenti-mACE2 compared with HFD + Lenti-GFP mice. Statistical significance: *P < 0.05, ***P < 0.001 vs. RD + Lenti-GFP; #P < 0.05, ##P < 0.01 vs. HFD + Lenti-GFP using repeated-measures ANOVA followed by Bonferroni’s post hoc test (A–D). One-way ANOVA followed by the Tukey multiple-comparison test (E).